Partnering
Partnering
Curileum discovers novel therapeutics for colorectal cancer and IBD to partner at preclinical development with pharmaceutical and biotechnology companies.
ULI-015 drug candidate
Novel small molecule drug with an excellent safety profile an efficacy profile to reduce development of bowel cancer
CSR-1 drug target programme
A soluble regulator (CSR-1) that Curileum discovered in Crohn’s patients’ anorectal tissue that drives overproduction of mast cells, leading to chronic inflammation.
